India prioritises GMP enforcement and biopharma push to protect pharmacy-of-the-world status
Pharma Secretary Manoj Joshi flagged mandatory Revised Schedule M compliance, stronger quality surveillance, possible trade-margin reforms and domestic API incentives. The government is also weighing a ₹10,000-crore biopharma mission, with implications for medicine availability, pricing and retail pharmacy supply.
India’s pharma secretary outlined stricter GMP enforcement, potential trade-margin reforms and domestic API incentives. The government is considering a ₹10,000-crore biopharma mission, while Jan Aushadhi procurement, drug-quality surveillance and GLP-1 manufacturing remain key retail medicine-supply issues.
Why this matters
No related recent Department of Pharmaceuticals signals were provided. The measures combine manufacturing-quality enforcement, domestic input resilience and potential pricing reforms affecting pharmacy supply.
Leadership is steady, with 958 signals in the past 90 days; no QoQ change figure was provided.